Skip to main content
. 2024 Nov 12;50:100887. doi: 10.1016/j.ctro.2024.100887

Table 1.

Patients’ characteristics. IGF-1: IGF-1 Insulin-like growth factor 1, ALT: Alanine transaminase, AST: Aspartate transaminase, GGT: Gamma-glutamyltransferase, INR: international normalized ratio, CTP: Child-Turcotte-Pugh, (BCLC) Barcelona Clinic Liver Cancer staging system, TACE: transarterial chemoembolization, SIRT: selective internal radiation therapy, AFP: Alpha-Fetoprotein, BMI: body mass index, EQD2: median equivalent dose in 2  Gy per fraction, Gy Gray.

Characteristic
Age 74 (50–87)
Gender
  • -

    Female

  • -

    Male
16
26
Cirrhosis:
 No cirrhosis:
 Cirrhosis		 7
(16.7 %)35
(83.3 %)
Median IGF-1 (range) 62.4 (21.3–161.4) ng/ml
Median Albumin (range) 3.75 (2.5–4.7) g/dl
Median Total Bilirubin (range) 0.81 (0.21–3.38) mg/dl
Median ALT (range) 29 (10–211) U/L
Median AST (range) 43 (18–132) U/L
Median GGT (range) 175 (14–909) U/L
Median INR 1.16 (0.97–2.44)
Ascites:
  • -

    No

  • -

    Mild

  • -

    Moderate to sever
31
3
8
CTP score
  • -

    A

  • -

    B

  • -

    C
27
12
3
IGF1-CTP score:
  • -

    A

  • -

    B

  • -

    C
26
12
4
Change in CTP score 3 months post SBRT.
unchanged
  • -

    1 point increase

  • -

    2 points increase.

  • -

    I point decrease (improvement)
28
4
1
2
Tumor size:
  • -

    <2 cm

  • -

    2–5 cm

  • -

    >5
8
16
18
BCLC Stage:
 A
 B
 C
 D
15
18
6
3
Prior Therapy:
 No
 Yes:
  Surgical resection
SIRT
  Systemic therapy
  Thermal ablation
  TACE
16

26
9
1
4
1
14
Therapy after SBRT
 No

 Yes:
  Systemic therapy
  Second course SBRT
  Thermal ablation
  Liver Transplant
23

19
10
3
4
4
Median Liver volume (range) 1407 (657–2545) cm3
Median Tumor volume (range) 20.3 (0.7–981) cm3
Median AFP (range) 11.5 (2.4–9066) ng/ml
Sarcopenia
  • -

    Yes

  • -

    No
19
23
Median BMI (range) 25.7 (17.58–43.95) kg/m2
Median Physical prescribed dose
Median number of fractionsMedina EQD2
(range)		 40 (18–50) Gy5
(1–8) Fractions60
(31.25–83.3) Gy